- Home
- XPER vs URGN Comparison
XPER vs URGN Comparison
Compare XPER & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPER
- URGN
- Stock Information
- Founded
- XPER 1990
- URGN 2004
- Country
- XPER United States
- URGN United States
- Employees
- XPER N/A
- URGN N/A
- Industry
- XPER Semiconductors
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- XPER Technology
- URGN Health Care
- Exchange
- XPER Nasdaq
- URGN Nasdaq
- Market Cap
- XPER 463.5M
- URGN 465.9M
- IPO Year
- XPER 2003
- URGN 2017
- Fundamental
- Price
- XPER $6.68
- URGN $10.05
- Analyst Decision
- XPER Strong Buy
- URGN Strong Buy
- Analyst Count
- XPER 3
- URGN 7
- Target Price
- XPER $19.00
- URGN $37.21
- AVG Volume (30 Days)
- XPER 337.1K
- URGN 487.2K
- Earning Date
- XPER 05-07-2025
- URGN 05-12-2025
- Dividend Yield
- XPER N/A
- URGN N/A
- EPS Growth
- XPER N/A
- URGN N/A
- EPS
- XPER N/A
- URGN N/A
- Revenue
- XPER $493,688,000.00
- URGN $90,398,000.00
- Revenue This Year
- XPER $0.74
- URGN $38.65
- Revenue Next Year
- XPER $8.45
- URGN $118.69
- P/E Ratio
- XPER N/A
- URGN N/A
- Revenue Growth
- XPER N/A
- URGN 9.29
- 52 Week Low
- XPER $6.29
- URGN $8.94
- 52 Week High
- XPER $11.39
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- XPER 35.13
- URGN 45.94
- Support Level
- XPER $6.36
- URGN $9.36
- Resistance Level
- XPER $6.63
- URGN $10.83
- Average True Range (ATR)
- XPER 0.37
- URGN 0.78
- MACD
- XPER -0.00
- URGN -0.06
- Stochastic Oscillator
- XPER 22.08
- URGN 45.12
About XPER Xperi Inc.
Xperi Inc consumer and entertainment technology company. Its offering comprises a portfolio of software and services. Its business is divided into four categories based on the products delivered and customers served: Pay-TV, Consumer Electronics, Connected Car, and Platform Solutions. It generates the majority of its revenue from the Consumer Electronics segment.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.